Nexien Biopharma Net Income vs. Beta

NXEN Stock  USD 0.01  0.01  25.00%   
Based on the key profitability measurements obtained from Nexien Biopharma's financial statements, Nexien Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Nexien Biopharma's ability to earn profits and add value for shareholders.
For Nexien Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nexien Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nexien Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nexien Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nexien Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between Nexien Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexien Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexien Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Nexien Biopharma Beta vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Nexien Biopharma's current stock value. Our valuation model uses many indicators to compare Nexien Biopharma value to that of its competitors to determine the firm's financial worth.
Nexien Biopharma is regarded third in net income category among its peers. It is regarded fourth in beta category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nexien Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nexien Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Nexien Beta vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Nexien Biopharma

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(626.36 K)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Nexien Biopharma

Beta

 = 

Covariance

Variance

 = 
1.48
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Nexien Beta Comparison

Nexien Biopharma is currently under evaluation in beta category among its peers.

Beta Analysis

As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nexien Biopharma will likely underperform.

Nexien Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Nexien Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nexien Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Nexien Biopharma's change in net profit over the period of time. It can combine multiple indicators of Nexien Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Nexien Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Nexien Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nexien Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nexien Biopharma's important profitability drivers and their relationship over time.

Use Nexien Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.

Nexien Biopharma Pair Trading

Nexien Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Nexien Biopharma position

In addition to having Nexien Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Care ETFs Thematic Idea Now

Health Care ETFs
Health Care ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Nexien Pink Sheet

To fully project Nexien Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nexien Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nexien Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Nexien Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Nexien Biopharma investors may work on each financial statement separately, they are all related. The changes in Nexien Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nexien Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.